Skip to Main Content

Paper Details

Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure.
J Card Fail
1
2022
HF, HFrEF, Heart Failure, SGLT-2, dapagliflozin, diabetes, glucose, heart failure, patient, patients, sodium, sodium-glucose cotransporter-2, type 1 diabetes, women
Author NameAffiliation
Adam D DeVoreDuke University School of Medicine, North Carolina Duke Clinical Research Institute
Paul A HeidenreichStanford University School of Medicine
Karen E Joynt MaddoxWashington University School of Medicine
Pamela N PetersonDenver Health Medical Center, Anschutz Medical Center
Gregg C FonarowAhmanson-university of california los angeles Cardiomyopathy Center, University of California
Gregg C FonarowAhmanson-university of california los angeles Cardiomyopathy Center, University of California
  • 1 - 6

Datasets

Release 1.2